VGI Health Technology (XNEC:VTL) Current Accrued Expense : A$0.00 Mil (As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Current Accrued Expense?

VGI Health Technology's Current Accrued Expense for the quarter that ended in . 20 was A$0.00 Mil.

VGI Health Technology Current Accrued Expense Historical Data

The historical data trend for VGI Health Technology's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Current Accrued Expense Chart

VGI Health Technology Annual Data

Trend

Current Accrued Expense

VGI Health Technology Semi-Annual Data

Current Accrued Expense

VGI Health Technology Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

VGI Health Technology Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines